CT041

Generic Name: CT041

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: CT041 is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Around the Helix: Cell and Gene Therapy Company Updates – August 28, 2024

Cell and gene therapy sectors are rapidly advancing, with approvals, clinical trials, and new therapies emerging. Notable developments include Legend Biotech's Carvykti approval in China, JW Therapeutics' relma-cel approval for MCL, Galapagos' GLPG5101 IND clearance, CARsgen's satri-cel trial enrollment completion, Tome Biosciences' layoffs, Tern Therapeutics' launch with $15 million, Navigator Medicines' $100 million series A, and Borealis Biosciences' $150 million Series A funding.

Related Clinical Trials:

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy